noninvasive respiratory support
Hypoxaemic failure → HFNC (over conventional O₂ and over NIV). Hypercapnic acidotic COPD (pH ≤7.35) → BiPAP (strong, high certainty; NIV first, HFNC only if NIV fails or isn’t tolerated). Cardiogenic pulmonary oedema → CPAP or BiPAP (strong). After extubation: low/moderate risk → HFNC; high risk → prophylactic NIV. Don’t use NIV for established post-extubation failure or for non-acidotic hypercapnia. Set a time limit: reassess at 1–2 h, and intubate early rather than late when it isn’t working.
which device for which patient
| scenario | first choice | strength | notes |
|---|---|---|---|
| de novo hypoxaemic failure (pneumonia, early ARDS) | HFNC | ERS conditional (vs COT moderate; vs NIV very low certainty); ESICM strong vs COT (less intubation); SSC 2026 applies it to P/F <200; ESICM no recommendation HFNC vs NIV | no mortality difference; fewer intubations. ERS/ATS 2017 makes no NIV recommendation for de novo failure |
| COPD, pH ≤7.35, PaCO₂ >45, RR >20–24 | BiPAP | strong, high | no pH floor, but the lower the pH the closer to intubation. Also before intubation unless crashing |
| COPD hypercapnic, not acidotic | no NIV | conditional against | treat the exacerbation, controlled O₂ 88–92% |
| cardiogenic pulmonary oedema | CPAP or BiPAP | strong | mortality RR 0.80; not in cardiogenic shock → acute decompensated heart failure |
| immunocompromised | HFNC or early NIV | NIV conditional (2017) | hypoxaemic, so the HFNC-over-NIV recommendation (2022) applies too |
| post-operative ARF (abdominal, thoracic, cardiac) | NIV or HFNC | conditional | source control first (anastomotic leak, collection). Upper GI surgery isn’t a contraindication if the surgeon agrees |
| post-extubation, low/moderate risk | HFNC | conditional | over COT; prophylactic NIV not suggested |
| post-operative, low risk | COT or HFNC | conditional | |
| post-extubation, high risk (age >65, cardiac or respiratory disease, hypercapnia) | NIV, prophylactic | ERS/ATS conditional; CHEST/ATS 2017 strong | HFNC if NIV contraindicated; HFNC between NIV sessions |
| established post-extubation failure | reintubate | conditional against NIV | NIV here delayed reintubation and increased mortality |
| weaning hypercapnic patients | extubate to NIV | conditional | |
| chest trauma | NIV (pain controlled) | conditional | |
| asthma | cautious trial only | no recommendation | → acute asthma |
| palliative dyspnoea (terminal cancer) | NIV if it helps the symptom | conditional | lowers opioid needs; not if it prolongs dying against goals |
| non-intubated hypoxaemic failure (sepsis, COVID-19) | trial of awake proning | SSC 2026 conditional, very low; ESICM suggests in COVID-19 | |
| COVID-19 hypoxaemia | CPAP/NIV or HFNC | ESICM weak (CPAP less intubation) |
HFNC
- heated, humidified gas at up to 60 L/min with FiO₂ up to 1.0. High flow meets peak inspiratory demand, so FiO₂ is what’s set. It washes out nasopharyngeal dead space (↓ PaCO₂ slightly), adds a little PEEP (~2–5 cmH₂O, mouth closed) and is comfortable, so it’s tolerated for days
- start at 50–60 L/min and FiO₂ to SpO₂ 92–96% (88–92% if hypercapnia risk); wean FiO₂ first, then flow
- FLORALI (2015): HFNC vs O₂ vs NIV in non-hypercapnic hypoxaemic failure. Intubation was similar overall, lower with HFNC when P/F ≤200, and 90-day mortality was lower with HFNC than with either. The likely reason NIV loses: large tidal volumes on NIV injure the lung (patient self-inflicted lung injury)
- ROX index = (SpO₂/FiO₂) ÷ RR. ≥4.88 at 2, 6 or 12 h predicts HFNC success; <3.85 at 12 h → intubate (Roca, AJRCCM. 2019)
- aerosol-generating: airborne precautions in suspected airborne infection
- use HFNC between NIV sessions (meals, mask breaks)
NIV (CPAP and BiPAP)
- CPAP: one pressure. Recruits alveoli and cuts LV afterload and preload, which is ideal in cardiogenic pulmonary oedema. Adds no ventilation
- BiPAP: EPAP (= PEEP) + IPAP. The gap (pressure support) carries ventilation and clears CO₂. Typical start is IPAP 10–12 / EPAP 4–5 cmH₂O ; raise IPAP in steps of 2 to target RR and pH, and raise EPAP for oxygenation or to splint the upper airway in obstructive sleep apnoea. Oronasal mask
- COPD logic: tired muscles under dynamic hyperinflation. Pressure support offloads them, and EPAP offsets intrinsic PEEP, reducing the effort needed to trigger each breath
Contraindications (most are relative): cardiac or respiratory arrest; can’t protect the airway or clear secretions; vomiting or upper GI bleed; facial trauma, burns or surgery; fixed upper airway obstruction; haemodynamic instability; untreated pneumothorax; uncooperative or agitated. A drowsy patient with hypercapnic encephalopathy is the exception: a closely monitored trial is reasonable, because CO₂ clearance often wakes them.
failure: when to stop and intubate
- reassess at 1–2 h: pH and PaCO₂ not improving (COPD), RR still high, accessory muscles, rising FiO₂, falling consciousness, can’t tolerate the mask, haemodynamic instability
- hypoxaemic failure: large expired tidal volumes on NIV predict failure, and a delayed intubation worsens outcome. Set the decision point up front
- decide the ceiling of care (NIV as ceiling vs full escalation) at the start → goals of care
Intubation and invasive ventilation: mechanical ventilation. ARDS on HFNC or NIV meets the global definition: ards.
Prepared 2026-10-29. Not yet verified — check every number against the sources.